Neptune Medical recently secured $97 million in Series D financing and launched a subsidiary, Jupiter Endovascular Inc., marking a strategic move to enhance its focus on gastrointestinal (GI) robotics while enabling Jupiter to advance in endovascular treatments. Neptune’s founder and CEO, Alex Tilson, emphasized that these developments will allow both companies to innovate within their respective fields.
The formation of Jupiter Endovascular follows Neptune’s recent appointment of Dr. Fred Moll, a surgical robotics pioneer, as chair of its board. Moll described the spinout as a strategic decision that will provide Jupiter with the resources and leadership needed to revolutionize endovascular therapies, while Neptune continues to focus on breakthroughs in GI robotics.
Jupiter Endovascular is pioneering a new generation of endovascular procedures with its Endoportal Control technology. (Source: Jupiter Endovascular)
Jupiter Endovascular exited stealth mode with $21 million in new financing and is developing the Endoportal Control platform. This technology aims to provide the precision of direct surgical access in catheter-based surgeries, enhancing the stability and control required in complex cardiovascular procedures. The company plans to use its new funding for an upcoming pivotal trial focused on pulmonary embolism, as well as for expanding the clinical applications of its technology.
Carl J. St. Bernard, recently appointed CEO of Jupiter Endovascular, highlighted the potential of the Endoportal Control technology to transform cardiovascular treatment by offering a minimally invasive yet highly controlled approach to delivering therapies.
The financing rounds for Neptune and Jupiter were supported by investors such as Sonder Capital and Olympus Corporation of the Americas. Sonder Capital’s managing partner, Kate Garrett, noted that Jupiter’s innovative approach could address significant unmet clinical needs, particularly in treating diseases in complex cardiovascular anatomies. Sonder Capital, co-founded by Moll, has a history of investing in healthcare technology companies, including Intuitive Surgical and Auris Medical.
Use case scenarios
The Endoportal Control technology from Jupiter Endovascular could have several impactful use case scenarios:
- Pulmonary Embolism Treatment: The technology could offer precise control in catheter-based procedures to remove blood clots in the lungs, reducing risks associated with traditional surgeries.
- Aortic Aneurysm Repair: By enhancing stability and precision, Endoportal Control could improve the accuracy of stent placements in the treatment of aortic aneurysms.
- Coronary Artery Disease: The technology could allow for more controlled and minimally invasive interventions in treating blocked coronary arteries, potentially improving outcomes for patients with heart disease.
- Complex Cardiovascular Procedures: It could be used in challenging cases involving intricate or hard-to-reach cardiovascular anatomies, providing the precision needed to safely deliver treatments.
- Stroke Intervention: Endoportal Control might facilitate the removal of clots from the brain’s arteries, improving the effectiveness of stroke interventions and reducing the risk of damage during the procedure.
These scenarios highlight the potential for Endoportal Control to transform how complex cardiovascular conditions are treated, making procedures safer and more effective.